Spot Bitcoin ETFs Debut on U.S. Exchanges Following Landmark SEC Approval
Summary:
The U.S. Securities and Exchange Commission (SEC) approved the listing of multiple spot Bitcoin exchange-traded funds (ETFs). Data from various stock exchanges shows shares of multiple Bitcoin ETFs, including those from ARK 21Shares, Invesco Galaxy, WisdomTree, Fidelity, and Franklin Temple, starting trade. Shares from Valkyrie Bitcoin Fund, iShares Bitcoin Trust, Grayscale Investments, Bitwise Bitcoin Trust, and Hashdex Bitcoin Futures ETF also made their appearance on the indices.
In a ground-breaking development this January 10, the U.S. Securities and Exchange Commission (SEC) has given the green light for the listing of multiple spot Bitcoin (BTC) exchange-traded funds, which have now started appearing on exchanges. On January 11, at 2:45 pm UTC, data from Cboe BZX Exchange revealed that the Bitcoin ETF shares from ARK 21Shares, trading under ARKB, were on the exchange at $50.18, Invesco Galaxy's at $49.59 under BTCO, WisdomTree at $52.13 as BTCW, Fidelity listed at $44.40 as FBTC, and Franklin Temple under EZBC were at $28.48. However, VanEck's spot BTC ETF, trading under HODL, was not visible during the report and set to debut at $54.92.
On the Nasdaq Stock Market, Valkyrie Bitcoin Fund shares started their journey on the index under BRRR, beginning in the pre-market at approximately $20, but later fell to $14.10, as of the time of this report. The world’s largest asset manager, BlackRock's iShares Bitcoin Trust shares, bearing the ticker IBIT, witnessed an approximate 22% surge in some pre-market trade, standing at $28.64 when reported. Meanwhile, Grayscale Investments' spot Bitcoin ETF, another significant contributor to gaining the SEC's approval, listed at $42.25 as GBTC on the New York Stock Exchange Arca, climbing to $42.97 during the report. The Bitwise Bitcoin Trust shares also joined the trade at $26.80 under BITB, along with Hashdex Bitcoin Futures ETF, trading at $60.00 as DEFI while holding spot BTC following the SEC's approval.
This is an evolving story and more information will be added as it surfaces.
Published At
1/11/2024 6:22:48 PM
Disclaimer: Algoine does not endorse any content or product on this page. Readers should conduct their own research before taking any actions related to the asset, company, or any information in this article and assume full responsibility for their decisions. This article should not be considered as investment advice. Our news is prepared with AI support.
Do you suspect this content may be misleading, incomplete, or inappropriate in any way, requiring modification or removal?
We appreciate your report.